List view / Grid view
In this issue is a discussion on the promise of virally vectored DNA and mRNA vaccines to combat COVID-19 as well as articles on how packaging could help to ensure patient adherence, regulatory issues for medicines and diagnostics during the pandemic and the benefits of digitalising the pharmaceutical supply chain.…
Dr Saurabh Kumar Banerjee explains how Raman spectroscopy can be utilised to analyse medicine quality and detect counterfeit drugs over the course of the COVID-19 pandemic.
A new infographic from Study Medicine Europe reveals how blockchain can optimise the healthcare and pharma industries. Here, the information is broken down and discussed.
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
A new paper has suggested that pay-for-delay deals could be replaced with a challenger-based system to improve access to generic drugs.
Alina Dvoretskaya describes how 3D technologies are used in pharmacology and the benefits these offer to the healthcare industry.
Tim Wilsdon and Ryan Lawlor from Charles River Associates explain why price-based procurement strategies can limit the long-term effectiveness and sustainability of vaccine programmes.
A study that analysed QA/QC incidents at several biomanufacturing plants has revealed how companies can best hope to detect and mitigate virus contamination.
Mike Owen analyses how smart product information (PIM) management could be crucial in the future of pharma, given how large the industry continues to grow.
Scientists have designed and synthesised chains of molecules for the purpose of drug delivery with a precise sequence and length to protect DNA nanostructures from degradation under biomedically relevant conditions.
Dr Saurabh Kumar Banerjee outlines the impact of COVID-19 on immunisation programmes in India and how organisations can hope to mitigate the consequences of missed vaccine doses.
The huge increase in demand for hand sanitisers since the outbreak of the coronavirus pandemic has seen companies hard-pressed to cope with the logistics.
Smita Deshmukh describes the current state of the global drug intermediates market, while suggesting how it will grow in the future.
Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
A PricewaterhouseCoopers report has highlighted the directions that the growth of the contract development and manufacturing organisation (CDMO) outsourcing market will take in the near future.
